cyrilzakka/clinical-trials huggingface dataset:
Body Contouring After Bariatric Surgeries in Jordan

This study aimed to describe Jordanians' awareness and knowledge of body-contouring surgeries and estimate their prevalence. Additionally, we aimed to identify the limitations reported by our population and compare them with those reported in the literature.

We aimed to reach out to 351 patients who underwent bariatric surgery at JUH as well as an additional 100 patients who underwent BS at one of the largest private medical facilities in Amman between January and June of 2021. We distributed a validated questionnaire to all patients. Of the 451 patients, 305 completed the questionnaire (response rate: 67.6%). The inclusion criteria were age 13-63 years, BS type (sleeve gastrectomy or Roux-en-Y bypass), and completion of the questionnaire. Responses that did not meet these criteria or contained duplicates were excluded (n=11). The remaining 294 responses were collected and entered into a database for the analysis.Three main variables were assessed in each group in addition to multiple other observations. The main variables were sex, marital status, and employment status.

Eligibility Criteria:
Inclusion Criteria:

* Age 13-63 years
* Bariatric surgery type (LSG or RYGB)

Exclusion Criteria:

* Incomplete or duplicate reponses
* Bariatric surgery ype (Gastric band)
Lateral Ridge Augmentation Using Two Graft Combination and a Cross-linked Collagen Membrane

To treat resorbed alveolar ridges, many surgical procedures are available in the literature such as ridge splitting, distraction osteogenesis, block grafting techniques and guided bone regeneration, which is the most documented technique. Various grafting materials are available but there is a lack of evidence on the superiority of a material or a combination of materials.

Bone width at the implant site is an important prerequisite for a predictable and long-term prognosis in implant dentistry. Different types of membranes and bone grafts are used in the GBR procedure. However, there is a lack of studies in the literature about the combination allograft/xenograft. The aim of the present trial is to compare two different bone graft combinations (autogenous-xenogeneic and allogeneic-xenogeneic) covered with a cross-linked collagen membrane in a horizontal alveolar ridge augmentation (without simultaneous implant placement).

Eligibility Criteria:
Inclusion Criteria:

* Healthy patients, non-smokers or smokers \<10 cigarettes/day.
* Age between 20 and 75.
* Full mouth bleeding score (FmBS) \<20 %.
* Full mouth plaque score (FmPS) \<15%.
* Residual bone width \< 5 mm and adequate bone height in the maxilla and the mandible.
* Tooth extraction performed at least 6 weeks before surgery.
* Presence of enough teeth to support an occlusal stent/radiographic guide.

Exclusion Criteria:

* Systemic diseases.
* Heavy smokers (\> 10 cigarettes/day).
* History of radiotherapy in the head and neck region in the last 5 years.
* Active periodontitis on the remaining teeth.
* Pregnancy.
* Intake of medications that may have an effect on bone turnover and mucosal healing (i.e., tetracycline within the last month, steroids within the last 6 months, bisphosphonates or fluorides at bone therapeutic levels, vitamin D and metabolites at therapeutic levels within the last 6 months).
Webnovela for Hispanic Dementia Family Caregivers

Photozig and Stanford University are creating a new program for Hispanic dementia caregivers to help cope with caregiving, alleviate related stress, and enhance quality of life for caregivers, with funding from the National Institute on Aging. The program includes a new education online telenovela (Webnovela), online resources, handouts and a DVD (for users without Internet) on how to deal with caregiving stress and handle difficult situations.

The goal of Webnovela program is to evaluate and develop materials for helping caregivers to cope with caregiving, alleviate related distress, and improve their quality of life.

The investigators are evaluating different materials, which may provide caregiving strategies, practical tips and help to enhance caregivers' skills to deal with demanding tasks of caregiving, alleviate related stress, and improve quality of life.

Research Program Steps:

1. Caregivers will be asked some simple questions about themselves and their family members to see if they are eligible for the project (fill out Enrollment Form and Informed Consent).
2. A Program survey will be sent, which can be completed online, or returned in a pre-mailed envelope.
3. Participants will receive links to online resources, related materials and instructions. The investigators ask participants to access the online resources, read provided brochures and guides, and follow the instructions. Materials are expected to help participants in their caregiver role.
4. After completing the program, the second and final survey should be filled out online or returned by pre-mailed envelope.

Eligibility Criteria:
Inclusion Criteria:

* Care for an individual with Alzheimer's Disease or other dementia.
* Have Internet access or own a DVD player.
* Minimum age of 18 years old.
* Belong to Hispanic/Latino ethnic group.
* Spend at least 8 hours/week caring for a person with dementia, which may include assisting, watching, monitoring, or being available to help (e.g. during sleep time)

Exclusion Criteria:

* Severe psychological or physical illness.
* Inability to read and follow Spanish instructions.
* High level of depressive symptoms.
* Unwillingness to participate in all aspects of the study.
Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)

Familial Adenomatous Polyposis (FAP) is an autosomal dominant disorder characterized by the formation of multiple adenomatous colorectal polyps usually in the teenage years. Virtually, all patients with FAP will develop colorectal cancer on average by the 5th decade of life if prophylactic surgery is not performed. Besides, these individuals must have lifelong cancer surveillance of the remaining colorectum or ileum.

Use of nonsteroidal anti-inflammatory drug (NSAID), such as sulindac, or celecoxib, which selectively inhibits prostaglandin synthesis primarily via the inhibition of cyclogenase-2 (COX-2) have been shown to reduce the incidence and induce regression of adenomas in the rectum of patients with FAP. However, use of NSAIDs and COX-2 inhibitors is associated with significant comorbidity including renal and gastric toxicity and increased risk of vascular events. Therefore, identification of a chemopreventive agent that would have similar efficacy but less toxicity would enhance our ability to treat these patients. Therefore the following specific aim has been proposed:To determine in a randomized, double-blinded, placebo-controlled study the tolerability and efficacy of curcumin to regress intestinal adenomas by measuring duodenal and colorectal/ileal polyp number, and polyp size in patients with FAP.

Patients will be randomized to curcumin (2 curcumin pills twice a day for 12 months) or placebo (2 pills twice a day for 12 months). Besides, blood samples, risk factor questionnaire,and biopsies (upper endoscopy and sigmoidoscopy) will be obtained.

Eligibility Criteria:
Inclusion Criteria:

* 21-85 years with FAP (with an intact colon or who have had surgery)

Exclusion Criteria:

* Mentally incompetent
* Female patients of childbearing age not on effective birth control
* Patients with WBC \< 3,500/ml, platelet count \< 100,000/ml, BUN \> 25mg%, creatinine \> 1.5mg%
* Patients unable to stop NSAIDS or aspirin use for the duration of the study
* Malignancy other than nonmelanoma skin cancer
* Active bacterial infection
* Patients with GERD (Gastro esophageal reflux disease)
* Patients with a history of peptic (stomach or duodenal) ulcer disease
* Patients on Warfarin or anti-platelet drugs
Comparision of the Analgesic Effects of Intravenous Ibuprofen and Tenoxicam in Acute Migraine Attack

The aim of this clinical trial is to compare the efficacy of two different non-steroidal anti-inflammatory analgesic drugs in the palliation of headache in acute migraine attack. The main questions it aims to answer are:

1. Is there a difference between the efficacy of two different nonsteroidal anti-inflammatory analgesics?
2. Is there a significant difference between the side effects of two different nonsteroidal anti-inflammatory drugs? Researchers will compare intravenous tenoxicam to intravenous ibuprofen to see if tenoxicam works to treat migraine attack.

Treatments will;

1. be administered in 100 cc saline to ensure blinding in the group.
2. Randomisation will be done by closed envelope method.
3. Numerical Pain Scale (NRS) will be used to evaluate the analgesic efficacy of the drugs. NRS scores will be recorded in both groups before starting treatment (baseline) and at 30, 60 and 120 minutes after treatment.
4. Any side effects due to medication will be recorded.


Eligibility Criteria:
Inclusion Criteria:

* Being between the ages of 18-65.
* Having a known diagnosis of migraine.
* Exclusion of secondary causes to explain the headache in the emergency department.
* Having migraine during a migraine attack and not having received any medical treatment for migraine before the application.

Exclusion Criteria:

* Being under 18 years of age.
* Being pregnant or breastfeeding.
* Being admitted to the emergency department with headache due to causes other than migraine (secondary).
* Being admitted with an acute migraine attack and having used medication for migraine treatment within 12 hours before admission.
* Having a history of allergy to any of the drugs to be used in the study.
* Having a history of comorbidities for which the drugs to be used in the study are contraindicated.
Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)

The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.


Eligibility Criteria:
Inclusion Criteria:

* Has a diagnosis of Ankylosing Spondylitis (AS) based on the Modified New York Criteria for AS (1984).
* Must have a radiograph of SI joints (AP Pelvis) documenting diagnosis of AS.
* Has active disease despite nonsteroidal anti-inflammatory drug (NSAID) therapy or intolerant to NSAIDs.

Exclusion Criteria:

* History of known or suspected complete ankylosis of the spine.
* History of allergies, intolerance or hypersensitivity to lactose or tofacitinib.
* History of any other rheumatic disease.
* Any subject with condition affecting oral drug absorption.
Assessing Demographic Biases in Deep Learning Model for Fetal Growth Estimation in Clinical Practice. Patients Eligible for Inclusion Are Women with a Gestational Age Between 24-42 Weeks Undergoing a Third-trimester Growth Scan. the Image Data from the Scan Are Used to Calculate Fetal Weight.

The goal of this observational study is to compare a new artificial intelligence (AI) feedback tool with the traditional method for estimating fetal weight during ultrasound scans on pregnant women between 24-42 weeks of gestation. The study aims to investigate the presence of demographic bias in the AI model. The demographic factors examined in the study include Body Mass Index (BMI), the number of births, fetal age, mother\&#39;s age, fetal sex, and the presence of preeclampsia. Moreover, the study will compare the accuracy of the AI model and the Hadlock model, a fetal growth formula, in estimating fetal weight. Participants will have their ultrasound scans pseudonymized and securely stored on password-protected removable drives, ensuring their identity and privacy are maintained. Afterward, the ultrasound data will be sent to the Technical University of Denmark (DTU), where the AI model will analyze the images to estimate fetal weight.


Eligibility Criteria:
Inclusion Criteria:

* Women with gestational age between 24-42 weeks undergoing a third-trimester growth scan.

Exclusion Criteria:

* Women with multiple pregnancies.
Validation of a Questionnaire to Measure Cough Severity

To design and validate a questionnaire that allows objective assessment of the severity of chronic cough

Chronic cough is a common disease that has important consequences for patients, ranging from physical to psychological and social aspects. However, there is currently no tool to objectively validate cough severity.

The aim of the study is to design and validate a questionnaire to objectively assess the severity of chronic cough.

Eligibility Criteria:
Inclusion Criteria:

* Aged between 30 and 99 years
* Clinical diagnosis of chronic cough or healthy volunteers
* Good understanding of Spanish

Exclusion Criteria:

* Non-Spanish-speaking patients
* Inability to complete the questionnaires
* Failure to sign the informed consent form
Healthy4Baby: Preventing Postpartum Weight Retention Among Low-Income, Black Women

The purpose of this study is to assess the feasibility and efficacy of an electronically-mediated, pregnancy and postpartum, behavioral intervention program, compared to usual obstetric care, on changes in weight and cardiometabolic biomarkers among overweight and obese Black women.

Black women are in particular need for obesity prevention and treatment. Targeting the childbearing period has the potential to slow the accumulation of weight gain among this high risk group. Previous interventions to prevent postpartum weight retention among Blacks are sparse and limited by poor intervention adherence, high attrition, and failure to include pregnancy in the study design. The proposed research aims to overcome these shortcomings by developing an intervention that 1) focuses solely on Black women, 2) incorporates Black mothers' information needs, values, and social context, 3) uses technology to facilitate participant engagement, and 4) includes both the pregnancy and postpartum periods.

Eligibility Criteria:
Inclusion Criteria:

1. Pregnant African-American women at least 18 years of age
2. BMI at recruitment between 25.0-44.9 kg/m2
3. Singleton pregnancy
4. Gestational age of ≤ 20 weeks as determined by last menstrual period
5. Plan to carry the pregnancy to term and keep the baby
6. Own a cell phone with a text messaging plan
7. Member of Facebook social networking site
8. Able to participate in physical activity
9. Participants must be willing to comply with all study-related procedures

Exclusion Criteria:

1. BMI ≤ 24.9 or ≥ 45.0
2. Uncontrolled hypertension (systolic blood pressure \> 160 or diastolic blood pressure \> 95 mmHg). Participants with controlled hypertension on medication for at least three months are allowable.
3. Known atherosclerotic cardiovascular disease
4. Known congestive heart failure
5. Known diabetes mellitus (type 1 or type 2)
6. Uncontrolled thyroid disease. Participants with controlled thyroid disease on medication for at least three months are allowable.
7. Known cancer
8. Any major active rheumatologic, pulmonary, hepatic, dermatologic disease or inflammatory condition requiring steroids or immune modulating medications
9. History of testing HIV positive
10. Current smoker or tobacco user
11. Current or recent history (past 6 months) of drug or alcohol abuse or dependence
12. Participation in any weight control or investigational drug study within 6 weeks of screening
13. Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety for successful study participation
14. Gastrointestinal Disorders (gallbladder disease, Crohn's disease, etc)
15. Previous weight loss surgery
16. History of bulimia or anorexia
Alipogene Tiparvovec for the Treatment of LPLD Patients

The aim of the study is to provide further confirmatory evidence of clinical benefit in LPLD patients treated with alipogene tiparvovec by assessing both the "clinical response" (as defined by a range of parameters), and "the metabolic response" (postprandial CM metabolism) in LPLD patients with and without an immunosuppressant regimen.

This is a prospective, interventional, randomised, open-label, parallel group study evaluating the clinical response as well as the dynamics of postprandial chylomicron metabolism in patients treated with alipogene tiparvovec with and without immunosuppressants. The study will be conducted in 12 LPLD patients who will be randomised into the Immuno+ (cyclosporin and mycophenolate mofetil) or the Immuno- group.

Eligibility Criteria:
Main inclusion criteria are:

* Patients with a history of severe or multiple pancreatitis attacks despite dietary fat restriction.
* Genetically confirmed diagnosis of LPLD
* Post-heparin plasma LPL protein mass \> 5% of normal
* LPL activity ≤20% of normal (in post- heparin plasma)
* Fasting plasma TG concentration \>10 mmol/L.

Main exclusion criteria are:

* Females with a positive pregnancy test or who are breastfeeding, or on contraceptive use.
* Patients with a positive HIV, Hepatitis B, Hepatitis C or being positive for tuberculosis.
* Patients under treatment with antiplatelet or other anti-coagulants.
* Patient allergic to or having a condition that prohibits the use of immunosuppressants.
Efficacy of TACE With Endoscopic Therapy for Unresectable Hepatocellular Carcinoma

The study is aimed to explore the efficacy of transarterial chemoembolization (TACE) combined with endoscopic therapy for unresectable hepatocellular carcinoma (HCC) complicated with esophagogastric varices (EGV) and seek out predictors associated with survival.


Eligibility Criteria:
Inclusion Criteria:

* 1. HCC was diagnosed in accordance with the 2017 edition of diagnosis guidelines, all patients were in CNLC stage Ib to IIIa, and treated with TACE; 2. EGV was demonstrated through endoscopic examination; 3. Child-Pugh grade A or B, or grade C patients improved liver function to grade A or B through aggressive treatment; 4. age between 18 and 75 years.

Exclusion Criteria:

* 1. HCC with diffuse or distant metastasis, or with other systemic malignancies; 2. severe jaundice, hepatic encephalopathy, refractory ascites or hepatorenal syndrome; 3. severe cardiac, cerebrovascular, lung and renal diseases and cannot tolerate endoscopic treatment; 4. severe coagulation dysfunction; 5. severe infection, bleeding with unstable vital signs; 6. history of liver surgery; 7. cannot or refuse to sign the informed consent.
Combined Effects of Bioactive Compounds in Lipid Profile

The aim of this study is to demonstrate whether, along with dietary recommendations, Armolipid Plus ® can improve the profile of patients with elevated plasma LDL-C acting as a change of lifestyle therapy (TLC) according to the definition of Adult Treatment Panel III (ATP III)

Recently reported that the combination of extract of red yeast rice policosanol composed, berberine, folic acid and coenzyme Q10 (Armolipid Plus ®, Rottapharm) produced a significant improvement in lipid profile in patients with moderately elevated cholesterol levels of low density lipoprotein (LDL-C) plasma.

Taking into account the potential effect of Armolipid Plus ® on the lipid profile, it is important to investigate the effectiveness in the field of cardiovascular prevention to define its position in prevention programs.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients \> 18 years old
* LDL-c plasma levels ≥130 mg/dL and ≤ 189 mg/dL
* Patients not requiring lipid-lowering drug treatment according to ATPIII guidelines,that do not have cardiovascular disease, stroke or intermittent claudication, diabetes mellitus, renal or Patients who have demonstrated effects or contraindications to lipid-lowering drug therapy (in this case, treatment should be discontinued 1 month before baseline.
* Signed and dated informed consent before any study specific procedure.

Exclusion Criteria:

* Patients on drug therapy to reduce LDL-C, for example, statins, bile acid sequestrants, nicotinic acid, fibrates or similar (up to 1 month before baseline).
* History of cardiovascular disease, stroke or intermittent claudication.
* Diabetes mellitus (at least 2 blood fasting glucose greater than 126 mg / dL).
* Having taken any functional food with sterols, stanols or similar or any nutraceutical with lipid-lowering effects during the previous 7 days.
* Plasma levels of triglycerides \> 350 mg/dl
* Diagnosis of familial hypercholesterolemia
Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetes

Type 1 Diabetes is a chronic autoimmune disease. It results from autoimmune destruction of pancreatic Beta cells leading to absolute insulin insufficiency. The establishment of pluripotent like human stem cells derived from adipose tissue derived mesenchymal cell origin have introduced a new potential source for cell therapy in type 1 diabetic patients, especially in light of recent successes in producing glucose-sensitive insulin secreting cells and this will be the scope of this study. In the last decade, human clinical trials of introducing insulin producing stem cells from various origins were approved and conducted.

Differentiation of stem cells from various sources to form insulin-producing cells (IPCS) provides a new and promising strategy to reconstitute pancreatic endocrine function. Studies recently developed a multistep differentiation technique for the differentiation of human embryonic stem cells to form pancreatic progenitors. At the end of in vitro differentiation approximately 5% of cells became insulin positive.

Mesenchymal stem cells (MSCs) can be derived from various sources. MSCs are undifferentiated cells with multilinear potential, known for their immunomodulatory and regenerative properties . The bone marrow, adipose tissue, umbilical cord, liver cells, and endometrium are among several tissues that are rich in MSCs. Of these, the bone marrow and adipose tissues offer distinct advantages in view of their availability and abundance and the extent of their documentation.

In this study the investigators aim to obtain autologous differentiated insulin producing mesenchymal stem cells (derived from adipose tissue) and their introduction in human subjects with type 1 diabetes. The current study will assess of the ability of the transplanted cells to produce insulin both in vitro and in vivo. Post- transplant glycemic control will be assessed with possible amelioration of the standard treatment of type 1 diabetes.

Eligibility Criteria:
Inclusion Criteria:

* Type 1 diabetes

Exclusion Criteria:

* patients with other autoimmune diseases
* patients with micro or macro vascular complications
* patients with other chronic diseases